



SPOTLIGHT

QuantiFERON

Driving continuous innovation

Spotlight Session
May 7, 2026



Forward looking and intended use statements



Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Regulation G: In this presentation, QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. Adjusted results include adjusted net sales, adjusted gross income, adjusted net income, adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted operating income margin, adjusted net income before taxes, adjusted income tax, adjusted tax rate, adjusted EBITDA, adjusted EPS, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.


Latent TB market growth led by skin test conversion

\$1.6 bn annual latent TB market opportunity⁽¹⁾

Only ~40% of market converted from skin tests

~4-5% underlying market growth adds to expansion

Growing demand – especially immunocompromised and biologics patients




>75 mn latent TB tests annually


Opportunity to unlock >45 mn additional tests via skin test conversion and expand QFT leadership

(1) Latent TB testing total addressable market in 2026 | QFT – QuantiFERON


From first-mover to ecosystem leader




Creating a complete QuantiFERON ecosystem




Blood collection



Aliquotation




Incubation



Centrifugation



Detection



Data analysis

Current QuantiFERON workflow



Announcing a new QuantiFERON ecosystem



QuantiFERON differentiates beyond CD4/CD8

CD4/CD8 technology as clinical standard



Impaired CD4 responses relevant in some patient groups



CD4 and CD8 together required for a more complete immune response assessment



Only IGRA with **patented, optimized** CD4/CD8 stimulation



Protected by >120 patents beyond 2030 in >30 countries



QuantiFERON scales with LIAISON⁽¹⁾ Diasorin



Scales across all lab sizes:



LIAISON XS

Up to 85 tests/hour and >20 patients/hour



LIAISON XL

Up to 171 tests/hour and >40 patients/hour

CLIA – Chemiluminescence Immunoassay | (1) With LIAISON QuantiFERON-TB Gold Plus II

Expanded ecosystem enables full automation and improves efficiency



Addressing the need to **improve pre-analytical steps** in labs

QIAGEN **fully automates** the process with Inpeco and Diasorin partnerships

Process automation can be adapted to **specific customer needs**

Ambition to be the first FDA-approved, CE-marked **fully automated TB test**

Launch
2027




AI-enhanced data asset to advance clinical value




20+ years

Longitudinal TB data and experience, unique to QIAGEN



~13 mn patient records

Largest real-world U.S. TB dataset



CD4 and CD8 test results

Captured at scale across all records



QuantiFERON AI tool designed to create clinical value for physicians



Combines CD4, CD8 and other patient data



Shows risk score for TB progression



Links insights to CDC decision guidelines



Real-world records support FDA pathway

1

Leading latent TB test performance in a growing market

Differentiated science and expanded throughput options strengthen QuantiFERON's leadership

2

Advancing workflow automation

New Inpeco partnership move QuantiFERON and LIAISON toward a full ecosystem solution

3

Expanding AI-enabled clinical value

Risk stratification tool in development reinforces QuantiFERON's leadership in latent TB testing